CA2330719C - Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration - Google Patents

Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration Download PDF

Info

Publication number: CA2330719C
Authority: CA; Canada
Prior art keywords: ascorbate; acid; lysine; composition; carboxylic acid
Prior art date: 1997-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2330719

Other languages

English (en)

French (fr)

Other versions

CA2330719A1 (en

Inventor

Matthias Dr. Rath

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-08

Filing date

2001-01-11

Publication date

2008-07-08

1997-07-08 Priority claimed from EP00115643A external-priority patent/EP1068868A3/en

2001-01-11 Application filed by Individual filed Critical Individual

2002-01-20 Publication of CA2330719A1 publication Critical patent/CA2330719A1/en

2008-07-08 Application granted granted Critical

2008-07-08 Publication of CA2330719C publication Critical patent/CA2330719C/en

2021-01-11 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 26
102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 23
108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 23
210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 22
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 10
239000004472 Lysine Substances 0.000 title claims abstract description 10
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract description 58
235000010323 ascorbic acid Nutrition 0.000 title abstract description 29
239000011668 ascorbic acid Substances 0.000 title abstract description 29
229940072107 ascorbate Drugs 0.000 title abstract description 28
230000007850 degeneration Effects 0.000 title description 6
230000002195 synergetic effect Effects 0.000 title description 3
230000015556 catabolic process Effects 0.000 claims abstract description 14
238000006731 degradation reaction Methods 0.000 claims abstract description 14
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 9
102000008186 Collagen Human genes 0.000 claims description 18
108010035532 Collagen Proteins 0.000 claims description 18
229920001436 collagen Polymers 0.000 claims description 18
108060005980 Collagenase Proteins 0.000 claims description 13
102000029816 Collagenase Human genes 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 13
229960002424 collagenase Drugs 0.000 claims description 13
238000003786 synthesis reaction Methods 0.000 claims description 12
239000003963 antioxidant agent Substances 0.000 claims description 11
235000006708 antioxidants Nutrition 0.000 claims description 11
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 8
239000003112 inhibitor Substances 0.000 claims description 7
230000003078 antioxidant effect Effects 0.000 claims description 6
QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims description 5
229960003375 aminomethylbenzoic acid Drugs 0.000 claims description 5
239000003527 fibrinolytic agent Substances 0.000 claims description 5
230000003480 fibrinolytic effect Effects 0.000 claims description 5
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 5
229960000401 tranexamic acid Drugs 0.000 claims description 5
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 4
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
229960004308 acetylcysteine Drugs 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
-1 ascorbyl aminomethylcyclohexane carboxylic acid Chemical compound 0.000 claims description 4
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 4
150000001746 carotenes Chemical class 0.000 claims description 4
235000005473 carotenes Nutrition 0.000 claims description 4
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 4
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 3
229960003912 probucol Drugs 0.000 claims description 3
229910052711 selenium Inorganic materials 0.000 claims description 3
239000011669 selenium Substances 0.000 claims description 3
229940091258 selenium supplement Drugs 0.000 claims description 3
235000010384 tocopherol Nutrition 0.000 claims description 3
229960001295 tocopherol Drugs 0.000 claims description 3
229930003799 tocopherol Natural products 0.000 claims description 3
239000011732 tocopherol Substances 0.000 claims description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
VGKZBAMIYUHSMU-UHFFFAOYSA-N 4-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(NC(=O)N(CCCl)N=O)CC1 VGKZBAMIYUHSMU-UHFFFAOYSA-N 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
229940113721 aminocaproate Drugs 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
239000001117 sulphuric acid Substances 0.000 claims description 2
235000011149 sulphuric acid Nutrition 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 abstract description 24
201000011510 cancer Diseases 0.000 abstract description 17
201000010099 disease Diseases 0.000 abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
230000001575 pathological effect Effects 0.000 abstract description 11
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 8
230000002265 prevention Effects 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 abstract description 4
208000015181 infectious disease Diseases 0.000 abstract description 4
208000027866 inflammatory disease Diseases 0.000 abstract description 3
229940088594 vitamin Drugs 0.000 abstract description 3
229930003231 vitamin Natural products 0.000 abstract description 3
235000013343 vitamin Nutrition 0.000 abstract description 3
239000011782 vitamin Substances 0.000 abstract description 3
239000011573 trace mineral Substances 0.000 abstract description 2
235000013619 trace mineral Nutrition 0.000 abstract description 2
239000002874 hemostatic agent Substances 0.000 description 25
108010088842 Fibrinolysin Proteins 0.000 description 17
229940012957 plasmin Drugs 0.000 description 17
102100040214 Apolipoprotein(a) Human genes 0.000 description 15
150000003254 radicals Chemical class 0.000 description 15
101710115418 Apolipoprotein(a) Proteins 0.000 description 14
230000017854 proteolysis Effects 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
108010001014 Plasminogen Activators Proteins 0.000 description 9
102000001938 Plasminogen Activators Human genes 0.000 description 9
229940127126 plasminogen activator Drugs 0.000 description 9
239000000126 substance Substances 0.000 description 9
102000013566 Plasminogen Human genes 0.000 description 8
108010051456 Plasminogen Proteins 0.000 description 8
238000000034 method Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
229940049370 fibrinolysis inhibitor Drugs 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
108010029690 procollagenase Proteins 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000027455 binding Effects 0.000 description 4
238000009739 binding Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
150000003147 proline derivatives Chemical class 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000011382 collagen catabolic process Effects 0.000 description 3
210000004186 follicle cell Anatomy 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
108010012927 Apoprotein(a) Proteins 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000004365 Protease Substances 0.000 description 2
229960002684 aminocaproic acid Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
230000000988 hyperfibrinolytic effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
210000004681 ovum Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000003950 pathogenic mechanism Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
235000011649 selenium Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
108010033266 Lipoprotein(a) Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
101150082943 NAT1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229940097156 peroxyl Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000008354 tissue degradation Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000006032 tissue transformation Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA 2330719 1997-07-08 2001-01-11 Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration Expired - Fee Related CA2330719C (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00115643A EP1068868A3 (en)	1997-07-08	1997-07-08	Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
EP00115643.9		2000-07-20

Publications (2)

Publication Number	Publication Date
CA2330719A1 CA2330719A1 (en)	2002-01-20
CA2330719C true CA2330719C (en)	2008-07-08

Family

ID=8169313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2330719 Expired - Fee Related CA2330719C (en)	1997-07-08	2001-01-11	Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration

Country Status (3)

Country	Link
CA (1)	CA2330719C (cs)
CZ (1)	CZ2001193A3 (cs)
IL (1)	IL140947A (cs)

2001
- 2001-01-11 CA CA 2330719 patent/CA2330719C/en not_active Expired - Fee Related
- 2001-01-16 CZ CZ2001193A patent/CZ2001193A3/cs unknown
- 2001-01-17 IL IL140947A patent/IL140947A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2330719A1 (en)	2002-01-20
IL140947A (en)	2008-06-05
IL140947A0 (en)	2002-02-10
CZ2001193A3 (cs)	2002-03-13

Legal Events

Date	Code	Title	Description
2001-01-11	EEER	Examination request
2010-01-11	MKLA	Lapsed

Publication	Publication Date	Title
US6139847A (en)	2000-10-31	Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
Tessitore et al.	1994	Pharmacological interference with tissue hypercatabolism in tumour-bearing rats
RU2242232C2 (ru)	2004-12-20	Фармацевтические комбинации
Flordal et al.	1993	Use of desmopressin to prevent bleeding complications in patients treated with aspirin
Pollack	1982	Wound healing: a review. IV. Systemic medications affecting wound healing
EP1068868A2 (en)	2001-01-17	Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
Soloway et al.	1983	Thiotepa-induced myelosuppression: review of 670 bladder instillations
AU766089B2 (en)	2003-10-09	Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
US6974833B2 (en)	2005-12-13	Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
CN111093748A (zh)	2020-05-01	含有低浓度氙和氩的气体混合物提供神经保护作用而不抑制血栓溶解剂的催化活性
CA2330719C (en)	2008-07-08	Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration
PL212241B1 (pl)	2012-08-31	Złożony produkt leczniczy i jego zastosowanie
AU783520B2 (en)	2005-11-03	Synergistic compositions comprising ascorbate and lysine for states related to extra cellular matrix degeneration
Miyahara et al.	2007	Subcutaneous injection of heparin calcium controls chronic disseminated intravascular coagulation associated with inoperable dissecting aortic aneurysm in an outpatient clinic
Caraco et al.	1992	Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration
RU2268038C2 (ru)	2006-01-20	Синергичные композиции, содержащие аскорбат и лизин, для лечения состояний, связанных с деструкцией внеклеточного матрикса
HK1049111A1 (zh)	2003-05-02	用於與細胞外基質退化相關疾病的含有抗壞血酸鹽和賴氨酸的協同組合物
MXPA01000491A (es)	2003-06-19	Composiciones sinergeticas que comprenden ascorbato y lisina para los estados relacionados a la degeneracion de la matriz extracelular.
NL1017114C1 (nl)	2002-07-17	Synergetische samenstellingen die ascorbaat en lysine bevatten, voor toestanden die in verband staan met de degeneratie van de extracellulaire matrix.
JP2002212072A (ja)	2002-07-31	細胞外マトリックス変性に関連する状態のための、アスコルビン酸類及びリジンを含有する相乗作用調合物
Sakamoto et al.	1995	Inhibitory Effect of Argatroban on Thrombin-Antithrombin III Complex after Percutaneous Transluminal Coronary Angloplasty
ES2184593B2 (es)	2005-05-01	Uso de composiciones que comprenden inhibidores de la fibrinolisis y compuestos de ascorbato para el tratamiento del cancer.
KR20020061130A (ko)	2002-07-23	아스코르베이트 및 리신을 포함하는 세포외 매트릭스퇴행성 증상 치료용 상승효과 조성물
HRP20010023A2 (en)	2002-08-31	Ascorbate and lysine containing synergistic compositions for the states related to the degradation of the extracellular matrix
SK682001A3 (sk)	2002-08-06	Farmaceutická kompozícia obsahujúca askorbát a najmenej jeden inhibítor fibrinolýzy